参考文献/References:
1 Hirvonen J, Aaho S, Lumme V, et al. Measurement of striatal and thalamic dopamine D2receptor binding with 11C-raclopfide[J]. Nucl Med Commun, 2003, 24(12):1207-1214.
2 Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopfide and positron emission tomography[J]. Ann Neurol, 1992, 31(2):184-192.
3 Rinne JO, Laihinen A, Rinne UK, et al. D2 receptor changes during the progression of early Parkinson’s disease[J]. Mov Disord, 1993, 8(2):134-138.
4 Rinne JO, Laihinen A, Ruottinen H, et al. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson’s disease:a PET study with[11C]raclopride[J]. J Neurol Sci, 1995, 132(2):156-161.
5 Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson’s disease patients with and without dyskinesias[J]. Neurology, 1997,49(3):717-723.
6 Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naive parkinsonism:Diagnostic implications of the D2 receptor status[J]. Brain, 1993, 116(4):853-867.
7 Antonini A, Schwarz J, Oertel WH, et al. long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease:a study with positron emission tomography and[11C]raclopride[J]. Mov Disord, 1997, 12(1):33-38.
8 Goerendt IK, Messa C, Lawrence AD, et al. Dopamine release during sequential finger movements in health and Parkinson’s disease:a PET study[J]. Brain, 2003, 126(2):312-325.
9 Ouchi Y, Yoshikawa E, Futatsubashi M, et al. Effect of simple motor performance on regional dopamine release in the striatum in Parkinson disease patients and healthy subjects:a positron emission tomog-raphy study[J]. J Cereb Blood Flow Metab, 2002, 22(6):746-752.
10 Tedroff J, Pedersen M, Aquilonius SM, et al. Levodopa-induced changes in synaptic dopamine in patients with Parkinson’s disease as measured by[11C] raclopride displacement and PET[J]. Neurology, 1996, 46(5):1430-1436.
11 Fuente-Fernandez R, Lu JQ, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor flucmatinns in Parkinson’s disease:PET evidence of increased dopamine turnover[J]. Ann Neurol, 2001, 49(3):298-303.
12 Linazasoro G, Obeso JA, Gomez JC, et al. Modification of dopamine D2 receptor activity by pergolide in Parkinson’s disease:an in vivo study by PET[J]. Clin Neuropharmacol, 1999, 22(5):277-280.
13 Moresco RM, Volonte MA, Messa C, et al. New perspectives on neurochemical effects of amantadine in the brain of parkinsonian patients:a PET-[(11)C]raclopride study[J]. J Neural Transm, 2002,109(10):1265-1274.
14 Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson’s disease[J]. Ann Neurol,2003, 53(5):647-653.
15 Hilker R, Voges J, Ghaemi M, et al. Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans[J]. Mov Disord, 2003, 18(1):41-48.
16 Piccini P, Brooks D J, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient[J].Nat Neurosci, 1999, 2(12):1137-1140.
相似文献/References:
[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(1):338.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
[3]董爱生,田建明.PET、SPECT及MRS在帕金森病诊断中的应用[J].国际放射医学核医学杂志,2005,29(6):244.
DONG Ai-sheng,TIAN Jian-ming.The application of PET、SPECT and MRS in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(1):244.
[4]谭海波,刘兴党.PET在神经干细胞移植治疗帕金森病研究中的进展[J].国际放射医学核医学杂志,2004,28(6):253.
TAN Hai-bo,LIU Xing-dang.Progress of PET imaging in the study of neural stem cell transplantation treating Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(1):253.
[5]田季雨.PET在帕金森病病理机制研究中的应用近况[J].国际放射医学核医学杂志,2003,27(2):53.
TIAN Ji-yu.Recent application of PET in the pathological mechanisms of PD[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(1):53.
[6]张海琴.中枢多巴胺转运蛋白显像剂99TcmTRODAT-1[J].国际放射医学核医学杂志,2001,25(3):100.
ZHANG Hai-qin.99Tcm-TRODAT-1: the central dopamine transporter imaging agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(1):100.
[7]左传涛.18F—多巴PET在帕金森病中的应用[J].国际放射医学核医学杂志,2000,24(1):4.
ZUO Chuan-tao.The Applications of 18F-DOPA PET in Parkinson’s Disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):4.
[8]孙文善.几种新型的中枢多巴胺转运蛋白显像剂[J].国际放射医学核医学杂志,2000,24(2):62.
SUN Wen-shan.Several new imaging agents for central dopamine transporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(1):62.
[9]邓玮玮,张春银.放射性核素显像在帕金森病鉴别诊断中的应用[J].国际放射医学核医学杂志,2017,41(2):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
Deng Weiwei,Zhang Chunyin.Application of radionuclide imaging on differential diagnosis of Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(1):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
[10]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]